Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi mulls Lyxumia lixisenatide market positioning with ADA data

This article was originally published in Scrip

Executive Summary

Data unveiled at the American Diabetes Association (ADA) 71st scientific sessions suggests that while Lyxumia (lixisenatide), from Sanofi, dosed once daily had met its endpoint of non-inferiority to Byetta (exenatide) in the treatment of Type 2 diabetes, the real battle will be to take on Victoza, (liraglutide), the once daily injectable GLP-1 analogue from Novo Nordisk. Moreover, it is likely that Sanofi will not pursue obesity as a target indication for lixisenatide.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC013471

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel